Former Members

Dr Eduardo Alves dos Santos

Dr Eduardo Alves dos Santos

Posted 01/12/2015

Eduardo Alves’s research involved the development and test new vaccines against human malaria (Plasmodium vivax) by encoding candidate genes in recombinant virus (AdChOX1 and MVA). The efficacy and immunogenicity of those virus vaccines are tested in rodent models which are challenge with transgenic rodent malaria (P. berghei) expressing human malaria (P. vivax) vaccine candidates. This project allows the screening of many vaccine candidates ...

Dr Marcos Lázaro Moreli

Dr Marcos Lázaro Moreli

Posted 04/12/2015

Cloning and construction of viral-vectored vaccines against Chikungunya virus. Dengue vaccine production using Virus Like Particles (VLPs) Email: marcos.moreli@ndm.ox.ac.uk  

Dr Fabiana Leoratti

Dr Fabiana Leoratti

Posted 07/09/2015

Dr Fabiana Leoratti works on P Vivax Malaria, Dengue and Chagas. Malaria is one of the main global public health problems. The majority of malaria morbidity and mortality is caused by two of the five species of Plasmodium that infect humans, P. vivax and P. falciparum.  The essential role for changing this situation would be the development of effective malaria vaccines. The rupture of erythrocytic schizonts induces clinical malaria of a ...

Dr Eduardo Montoya-Diaz

Dr Eduardo Montoya-Diaz

Posted 01/12/2015

To date, vaccination remains the most effective way for control and prevention of infectious diseases and this approach has yet to demonstrate its potential for any parasitic disease, including malaria. Malaria caused by Plasmodium vivax seriously challenges human health, attacking 100 to 400 million people each year among the 2.5 billion living at endemic risk. P. vivax vaccines have rarely reached Phase I or II trials, the leading and most ...

Dr Elisangela Oliveira de Freitas

Dr Elisangela Oliveira de Freitas

Posted 01/12/2015

Plasmodium vivax is the second most prevalent species causing malaria in the world. Recent data estimates the occurrence of cases 132-391 million annually. The relative inefficiency of control measures currently employed requires the development of new prevention strategies, such as vaccines, new drugs and new insecticides. Studies in the past 20 years to the development a recombinant vaccine against human infection caused by Plasmodium ...